Wire · opportunities
Kyverna 'resetting conversation' with 1-year miv-cel data as autoimmune CAR-T peers hit ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 September 2026 · Fusion42 review
Kyverna Therapeutics reported one-year clinical data for its autoimmune CAR-T candidate miv-cel showing sustained efficacy and a strong safety profile, while competitors Novartis and Bristol Myers Squibb face safety setbacks in similar therapies. Kyverna plans to complete its FDA submission for stiff person syndrome (SPS) indication by Q4 2026.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You face a rare chance to lead autoimmune CAR-T with better safety data as Kyverna closes in on FDA approval. Competitors’ safety failures make this a narrow window to establish market leadership and define treatment standards.
◆ Coverage
2 sources · 24 Sep 2026
◆ Related on Wire
◆ Topics